Lion's mane mushroom improves Alzheimer's disease markers by stimulating NGF production, reducing amyloid-beta plaque accumulation, enhancing cholinergic neurotransmission, and promoting hippocampal neurogenesis — with effects confirmed in human trials for the pre-Alzheimer's stage of mild cognitive impairment.
Alzheimer's disease is the most common cause of dementia, affecting more than 55 million people worldwide and accounting for 60–70% of all dementia cases. It's a slowly progressive neurodegenerative condition characterized by the accumulation of amyloid-beta plaques and tau protein tangles in the brain, leading to gradual destruction of neurons — particularly the cholinergic neurons of the basal forebrain that are essential for memory and learning.
Modern medicine manages symptoms through cholinesterase inhibitors (donepezil, rivastigmine) and memantine, but no approved treatment stops or reverses the underlying neurodegeneration. This gap between symptom management and neuroprotection is where lion's mane research is most relevant.
How Alzheimer's Destroys the Brain: The NGF Connection
The neurons most selectively destroyed in early Alzheimer's disease — the cholinergic neurons of the basal forebrain — are among the most dependent on NGF (nerve growth factor) for survival. NGF is produced in the hippocampus and cortex and transported to the basal forebrain via retrograde axonal transport. When this transport system is disrupted — as it is in Alzheimer's disease — cholinergic neurons are deprived of their survival signal and begin to degenerate.
This is not a coincidence: it's one of the reasons cholinergic neurons are selectively vulnerable in Alzheimer's, and it's why NGF was extensively investigated as a potential Alzheimer's treatment in the 1990s and 2000s. Direct NGF infusion into the brain showed promising results in early trials but was impractical clinically. Lion's mane provides a dietary approach to the same problem: stimulating the brain's own NGF production from within, using compounds that cross the blood-brain barrier naturally.
Lion's Mane Compounds and Alzheimer's Biology
Hericenones (from the fruiting body) and erinacines (from the mycelium) address Alzheimer's pathology through several overlapping mechanisms.
NGF/BDNF stimulation: Both compound classes activate NGF and BDNF synthesis in astrocytes and hippocampal cells, providing the neurotrophic support that cholinergic neurons need to survive. Erinacin A has specifically been shown to increase NGF expression in the hippocampus and basal forebrain of aged mice (Tzeng et al., 2016, PMID 27350344).
Amyloid-beta reduction: Erinacin A treatment in Alzheimer's-model mice has been associated with reduced amyloid-beta plaque accumulation and lower expression of amyloid precursor protein processing enzymes. This is a direct attack on one of the two primary pathological hallmarks of Alzheimer's disease.
Cholinergic neuron protection: By maintaining NGF signaling, lion's mane helps preserve the survival of the basal forebrain cholinergic neurons that drive acetylcholine-dependent memory formation. This is mechanistically complementary to cholinesterase inhibitors, which increase acetylcholine availability — lion's mane supports the neurons that produce it.
The 2009 Japan Clinical Trial: Key Data
The most directly relevant human trial was conducted by Mori et al. (2009, PMID 18844328) at Hokuto Corporation in Japan. This double-blind, placebo-controlled study enrolled 30 adults aged 50–80 with mild cognitive impairment (MCI) — the transitional stage between normal aging and Alzheimer's disease.
Participants took either 3 g/day of Hericium erinaceus fruiting body powder (in tablet form) or placebo for 16 weeks. Cognitive function was assessed using the Revised Hasegawa Dementia Scale (HDS-R) at weeks 8, 12, and 16.
Results: the lion's mane group showed statistically significant improvements at all three assessment points compared to placebo. At week 16, a substantially higher proportion of participants in the lion's mane group showed meaningful improvement versus the placebo group. Critically, cognitive scores returned toward baseline within 4 weeks of cessation — confirming that ongoing supplementation was needed to maintain the benefit, consistent with the NGF-stimulation mechanism requiring continuous activation.
No serious adverse effects were detected throughout the trial. This remains the most rigorous human data point for lion's mane and cognitive impairment.
Erinacin A and Early Alzheimer's: Taiwan Research
A research group at Grape King Bio Ltd. (Taiwan) investigated erinacin A-enriched mycelium preparations in both animal Alzheimer's models and a small human study in early-onset Alzheimer's patients. The animal data showed reduced amyloid-beta accumulation, improved spatial memory performance, and preserved cholinergic neuron counts compared to untreated controls (Tzeng et al., 2016, PMID 27350344).
These findings establish erinacin A as the more specifically Alzheimer's-relevant compound in lion's mane, while hericenones provide broader cognitive support. Full-spectrum products combining fruiting body (hericenones) and quality mycelium (erinacines) are theoretically the most comprehensive choice for Alzheimer's-risk reduction goals.
Practical Guidance: Early Intervention and Realistic Expectations
The strongest case for lion's mane in Alzheimer's context is early intervention — before significant neurodegeneration has occurred. MCI patients and those with family history or genetic risk (APOE4 carriers) represent the population where neuroprotective supplementation could theoretically have the greatest impact, because there are still viable neurons to protect.
For individuals seeking to support cognitive health: 1–3 g/day of lion's mane fruiting body extract is the dose range used in clinical studies. Pair it with omega-3 fatty acids (supporting neuronal membrane health), B vitamins (especially B12 and folate, reducing homocysteine — an independent Alzheimer's risk factor), and regular aerobic exercise (the most consistently effective intervention for BDNF and neuroplasticity). Begin supplementation before any cognitive decline begins for maximum potential benefit.
You can find lion's mane products in our store:
1. Lion's mane fruits
2. Lion's mane capsules
3. Lion's mane extract
Frequently Asked Questions
Can lion's mane reverse Alzheimer's disease?
No — lion's mane cannot reverse Alzheimer's disease. There are no human trials demonstrating reversal of Alzheimer's pathology with any supplement. What the Mori 2009 trial does show is that lion's mane can improve cognitive function scores in mild cognitive impairment — the pre-Alzheimer's stage — with ongoing daily supplementation. This is consistent with neuroprotection and neuroplasticity support, not with reversal of established neurodegeneration.
Should I take lion's mane if I have a family history of Alzheimer's?
Lion's mane is a biologically plausible preventive supplement for people with Alzheimer's risk factors. Its NGF-stimulating effects support the cholinergic neuron health that Alzheimer's specifically destroys, and its BDNF activation supports hippocampal neurogenesis — the brain region damaged earliest in Alzheimer's. No trial has proven it prevents Alzheimer's in high-risk individuals, but the mechanisms are directly relevant to the disease pathway. Starting early, before any cognitive changes, is the most defensible approach.
How does lion's mane compare to Alzheimer's medications?
Pharmaceutical Alzheimer's treatments (donepezil, memantine, lecanemab) work by different mechanisms — cholinesterase inhibition, NMDA receptor modulation, and amyloid removal respectively. Lion's mane is not comparable in potency or clinical evidence for diagnosed Alzheimer's. In MCI, where no pharmaceutical has proven long-term benefit, lion's mane's human trial data (Mori 2009) is actually among the better available evidence for any intervention. For MCI specifically, it's a reasonable evidence-backed addition to a prevention-focused strategy.
How long does lion's mane take to show cognitive benefits?
The Mori 2009 trial showed statistically significant improvements at 8 weeks, with further gains at 12 and 16 weeks. Effects reversed within 4 weeks of stopping, suggesting benefits require continuous supplementation. For Alzheimer's risk reduction as a long-term strategy, the appropriate timeframe for evaluation is months to years rather than weeks — this is neuroprotection, not an acute intervention. Track cognitive function with standardized tools (MMSE, Montreal Cognitive Assessment) rather than subjective self-assessment.
Is erinacine-rich mycelium better than fruiting body for Alzheimer's?
For Alzheimer's-specific mechanisms, erinacin A (from mycelium) has more direct preclinical evidence — it's been shown to reduce amyloid-beta accumulation and protect cholinergic neurons in AD animal models. Fruiting body hericenones provide broader NGF stimulation. A full-spectrum product combining quality mycelium (erinacines) and fruiting body (hericenones) covers both mechanisms. Ensure any mycelium component specifies low starch content and verified erinacine concentration, not just «mycelium extract.»
Related Articles
Sources
- Mori K, et al. Improving effects of the mushroom Yamabushitake on mild cognitive impairment. Phytother Res. 2009. PMID 18844328
- Tzeng TT, et al. Erinacin A-Enriched Hericium erinaceus Mycelium and Cognitive Impairment. Int J Mol Sci. 2016. PMID 27350344
- Mori K, et al. Nerve growth factor-inducing activity of Hericium erinaceus. Biol Pharm Bull. 2008. PMID 18296328
- Lai PL, et al. Neurotrophic properties of the Lion's mane medicinal mushroom. Int J Med Mushrooms. 2013. PMID 24266378